Latest / The Well-Built Life / Unlocking the Mystery of DiGeorge Syndrome
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:10Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:18Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:23Speaker 1: and let's dive in. Hello Thomas, it's fascinating to dive
- 0:27Speaker 1: into the history of Digorge Syndrome. As we start this section,
- 0:31Speaker 1: can you give us a quick rundown of when and
- 0:34Speaker 1: how this syndrome was first recognized by medical science?
- 0:37Speaker 2: Sure, Rachel. Let's go back to the 1960s. It all
- 0:42Speaker 2: began with Dr. Angelo DeGeorge who, in his pioneering work,
- 0:46Speaker 2: started laying the foundational stones for understanding what would later
- 0:50Speaker 2: be called DeGeorge syndrome. But the formal recognition didn't come
- 0:54Speaker 2: until much later, right?
- 0:55Speaker 1: That's exactly right.
- 0:56Speaker 2: Dr.
- 0:57Speaker 1: DeGeorge's work was really the starting point but the identification
- 1:00Speaker 1: of the specific genetic defect came much later. In 1990,
- 1:05Speaker 1: the microdolation on chromosome 22q11. 2 was finally pinpointed, marking a
- 1:11Speaker 1: significant breakthrough, and just three years later, in 1993, the
- 1:16Speaker 1: TBX1 gene was identified as a key player in the syndrome.
- 1:20Speaker 2: Exactly. The TBX1 gene is crucial because it regulates the
- 1:25Speaker 2: development of the thymus and parathyroid glands, which are vital
- 1:30Speaker 2: for immune function and hormone regulation. Without it, the development
- 1:35Speaker 2: of craniofacial structures and the heart can be severely impaired.
- 1:39Speaker 2: This discovery was a game changer in understanding the genetic
- 1:43Speaker 2: underpinnings of the syndrome.
- 1:44Speaker 1: Yes, and the impact of these discoveries on diagnostics and
- 1:48Speaker 1: treatment strategies has been substantial. With advancements in genetic testing,
- 1:53Speaker 1: we can now provide more accurate diagnoses and tailor treatments
- 1:56Speaker 1: better than ever before. But the journey from those early
- 1:59Speaker 1: days to where we stand now is truly remarkable. What
- 2:02Speaker 1: do you think has been the most significant development in
- 2:06Speaker 1: managing this syndrome?
- 2:07Speaker 2: Great question, Rachel. The ability to identify the syndrome prenatally
- 2:11Speaker 2: has been a huge leap. This means families can be
- 2:14Speaker 2: prepared early on and treatments can begin as soon as
- 2:18Speaker 2: the child is born. However, The variability in symptoms, even
- 2:22Speaker 2: with the same genetic defect, makes it tricky. The extent
- 2:25Speaker 2: of the deletion and its exact location can hugely impact
- 2:29Speaker 2: the severity and nature of the symptoms. This is one
- 2:33Speaker 2: of the key contradictions we face in the field.
- 2:35Speaker 1: Absolutely, Thomas. That variability is indeed a challenge. Let's talk
- 2:41Speaker 1: about some of the key mechanisms underlying Digorge syndrome. Can
- 2:46Speaker 1: you explain the role of neural crest cells? and the
- 2:49Speaker 1: TBX1 gene a bit more?
- 2:51Speaker 2: Sure. Neural crest cells are like the multitaskers of embryonic development.
- 2:57Speaker 2: They migrate extensively to form craniofacial structures and contribute to
- 3:02Speaker 2: the formation of the heart. The TBX1 gene is essential
- 3:06Speaker 2: for these cells to migrate correctly. When TBX1 is deleted
- 3:10Speaker 2: or not functioning properly, it leads to disruptions in thymus
- 3:14Speaker 2: and parathyroid development, which in turn impact immune function, and
- 3:19Speaker 2: calcium regulation.
- 3:20Speaker 1: Right, and that's the crucial nuance here. It's not just
- 3:24Speaker 1: about the absence of TBX1, but the cascade of effects
- 3:27Speaker 1: it has on the development and function of multiple organs.
- 3:31Speaker 1: The clinical manifestations can range widely, from heart defects and
- 3:35Speaker 1: cleft palate to thymic abnormalities and hypoparathyroidism. How does this
- 3:40Speaker 1: variability in symptoms affect management and treatment strategies?
- 3:44Speaker 2: Good point, Rachel. The wide spectrum of symptoms necessitates a
- 3:49Speaker 2: multidisciplinary approach. Cardiologists, endocrinologists, immunologists, and orthodontists all play crucial
- 3:56Speaker 2: roles in managing these patients. Therese stills some debate around
- 4:00Speaker 2: the most effective therapeutic methods, particularly when it comes to
- 4:04Speaker 2: addressing the developmental issues. Gene therapy and stem cell-based therapies
- 4:10Speaker 2: are areas of ongoing research. Yes.
- 4:12Speaker 1: The debate around therapeutic approaches is intense. Some argue that
- 4:17Speaker 1: early screening and intervention are key, while others wonder if
- 4:20Speaker 1: prenatal testing could prevent some of these issues altogether. Ethical
- 4:25Speaker 1: considerations come into play too, as we are dealing with
- 4:28Speaker 1: genetic information that could affect many aspects of a person's life.
- 4:32Speaker 2: Definitely, Rachel. Ethical concerns have to be addressed carefully. But
- 4:36Speaker 2: to get back to the science, we need to understand
- 4:38Speaker 2: more about the exact mechanisms that cause these disruptions. For instance,
- 4:43Speaker 2: can genetic testing accurately predict who will experience which symptoms?
- 4:47Speaker 2: And what about the potential of gene editing technologies? Could
- 4:50Speaker 2: they offer a cure in the future?
- 4:52Speaker 1: That's the kind of future outlook we are talking about, Thomas.
- 4:56Speaker 1: While we have made significant strides, Therese still a lot
- 4:59Speaker 1: to explore. With ongoing research and technological advancements, we are
- 5:04Speaker 1: hopeful that better treatments and even cures may be on
- 5:08Speaker 1: the horizon. It's an exciting time, and Therese so much potential.
- 5:12Speaker 1: for improving the quality of life for those affected by
- 5:15Speaker 1: Digorge syndrome. So, Thomas, let's dive into the heart of
- 5:19Speaker 1: the matter, literally and figuratively. The TBX1 gene plays a
- 5:23Speaker 1: crucial role in the development of the thymus and parathyroid glands.
- 5:27Speaker 1: Can you explain how exactly this gene affects these critical organs,
- 5:31Speaker 1: and what happens when it's deleted?
- 5:32Speaker 2: Absolutely, Rachel. The TBX1 gene is a transcription factor that
- 5:37Speaker 2: regulates the expression of other genes involved in neural crest
- 5:40Speaker 2: cell development. Neural crest cells are multipotent stem cells that
- 5:44Speaker 2: migrate and give rise to several key structures including parts
- 5:47Speaker 2: of the thymus and parathyroid glands. When the TBX1 gene
- 5:51Speaker 2: is deleted, these cells can't migrate properly, leading to thymic
- 5:56Speaker 2: hypoplasia and hypoparathyroidism.
- 5:58Speaker 1: That's fascinating. So, if the neural crest cells are crucial
- 6:02Speaker 1: for forming these glands, and they fail to migrate correctly
- 6:05Speaker 1: due to the deletion of TBX1, how does this impact
- 6:09Speaker 1: someone's health day?
- 6:12Speaker 2: Well, the thymus is a vital component of the immune system.
- 6:17Speaker 2: It's where T-cells mature and are trained to recognize foreign invaders.
- 6:22Speaker 2: With thymic hypoplasia, these T-cells don't develop properly, leading to immunodeficiency.
- 6:29Speaker 2: The parathyroid glands produce parathyroid hormone, PIF, which is essential
- 6:34Speaker 2: for calcium homeostasis. Without a functional parathyroid, calcium levels can drop,
- 6:40Speaker 2: leading to hypocalcemia and potential neurological symptoms.
- 6:44Speaker 1: That's a lot to unpack. So, you have mentioned that
- 6:47Speaker 1: the thymus and parathyroid glands develop from these neural crest cells,
- 6:51Speaker 1: and when these cells fail to migrate or function correctly,
- 6:54Speaker 1: it leads to specific symptoms. But how does this genetic
- 6:58Speaker 1: deletion play out in a real person's life?
- 7:00Speaker 2: Right. Let's take thymic abnormalities, for instance. About 80% of
- 7:05Speaker 2: individuals with Digorge syndrome have some form of thymic issue.
- 7:09Speaker 2: This can range from a thymus that is completely underdeveloped
- 7:13Speaker 2: to one that is present, but not fully functional. This
- 7:16Speaker 2: results in a weakened immune system, making the person more
- 7:20Speaker 2: susceptible to infections.
- 7:22Speaker 1: And what about the parathyroid issue? Are there any specific
- 7:25Speaker 1: symptoms or health impacts associated with hypoparathyroidism?
- 7:29Speaker 2: Hypoparathyroidism is a common feature in D. George syndrome, affecting
- 7:34Speaker 2: about 40 to 50% of cases. Symptoms can include muscle cramps, tetany,
- 7:40Speaker 2: and even seizures due to low calcium levels. Over time,
- 7:44Speaker 2: hypoparathyroidism can lead to dental and bone issues, which can
- 7:49Speaker 2: add to the overall health challenges faced by those with
- 7:52Speaker 2: the syndrome.
- 7:52Speaker 1: That paints a really complex picture. So, moving on to
- 7:56Speaker 1: the stakeholders, it seems like a multifaceted approach is needed.
- 8:01Speaker 1: Can you elaborate on the roles of geneticists, physicians, and
- 8:05Speaker 1: support organizations in managing Digorge syndrome?
- 8:09Speaker 2: Definitely. Geneticists and medical researchers are constantly advancing our understanding
- 8:15Speaker 2: of the genetic basis of the syndrome, which is crucial
- 8:18Speaker 2: for developing better diagnostics and treatments. Clinicians are on the
- 8:22Speaker 2: front lines, diagnosing and managing the broad spectrum of symptoms.
- 8:27Speaker 2: Support organizations provide resources, advocate for better care, and offer
- 8:33Speaker 2: emotional support to families.
- 8:35Speaker 1: And what role do pharmaceutical companies play? Are there any
- 8:39Speaker 1: therapeutic approaches that are currently in use or being developed?
- 8:44Speaker 2: Pharmaceutical companies play a significant role in developing and administering therapies.
- 8:49Speaker 2: Current approaches include surgical interventions to correct anatomical issues and
- 8:54Speaker 2: pharmacological treatments to manage symptoms like hypoparathyroidism. Terry's also interest
- 9:00Speaker 2: in gene therapy and stem cell-based therapies, which could potentially
- 9:05Speaker 2: offer more targeted and long-lasting solutions.
- 9:08Speaker 1: That's a lot of ground to cover. It seems like
- 9:10Speaker 1: Terry's still a lot of research to be done. What
- 9:13Speaker 1: are some of the key questions that researchers are currently
- 9:16Speaker 1: grappling with?
- 9:17Speaker 2: Exactly. Some of the big questions include understanding the precise
- 9:22Speaker 2: mechanisms by which TBX1 deletion disrupts neural crest cell migration.
- 9:27Speaker 2: Therese also debate about the reliability of genetic testing in forecasting,
- 9:32Speaker 2: the variability of symptoms, and, of course, Therese's ongoing research
- 9:37Speaker 2: into the most effective therapeutic strategies.
- 9:40Speaker 1: It's really encouraging to see the progress, but also sobering
- 9:43Speaker 1: to recognize the complexity of the challenges. Thank you, Thomas,
- 9:47Speaker 1: for walking us through this depth of information. This has
- 9:51Speaker 1: certainly given our listeners a more nuanced understanding of DeGeorge syndrome.
- 9:55Speaker 1: and the stakeholders involved. So, Thomas, we have covered the
- 9:59Speaker 1: basics of the genetic underpinnings and clinical manifestations, but there
- 10:04Speaker 1: is a lot more to explore, especially regarding the predictability
- 10:08Speaker 1: of the disease and the therapeutic strategies. Let's start with
- 10:12Speaker 1: genetic testing. How reliable are these tests? And do they
- 10:16Speaker 1: accurately forecast the variability of symptoms?
- 10:19Speaker 2: That's a great question, Rachel. The truth is, genetic testing
- 10:23Speaker 2: can be quite comprehensive, but it's not a crystal ball.
- 10:27Speaker 2: The variability in symptoms isn't always straightforward. For example, even
- 10:32Speaker 2: with the same size and location of the 22q11. 2 deletion,
- 10:36Speaker 2: some individuals might only have mild symptoms while others could
- 10:39Speaker 2: face severe health issues. This variability can also affect treatment outcomes,
- 10:45Speaker 2: complicating the therapeutic approach.
- 10:47Speaker 1: Yeah, that's a real head-scratcher. It seems like the variability
- 10:51Speaker 1: could impact both diagnostic and treatment plans. Transitioning to preventive strategies,
- 10:56Speaker 1: how effective are early screening programs? Are they cost-effective, and
- 11:01Speaker 1: do they provide enough actionable information?
- 11:03Speaker 2: Early screening programs are definitely a topic of debate. They
- 11:07Speaker 2: can catch issues like congenital heart defects early, which can
- 11:11Speaker 2: save lives. However, they might not be as effective in
- 11:14Speaker 2: predicting the full range of symptoms that can surface later
- 11:17Speaker 2: in life. The challenge lies in balancing the resources allocated
- 11:21Speaker 2: to early screening with the potential long-term benefits. For instance,
- 11:25Speaker 2: prenatal tests can provide some data, but they are not
- 11:28Speaker 2: always conclusive.
- 11:30Speaker 1: Exactly, which brings up an interesting contradiction. We have these
- 11:34Speaker 1: advanced prenatal screening tools, but they might not be sufficient
- 11:37Speaker 1: for a comprehensive understanding of a patient's future health. This
- 11:41Speaker 1: raises concerns about whether we should rely solely on these
- 11:44Speaker 1: tests or look at other factors too.
- 11:47Speaker 2: Absolutely. And this segues nicely into the debate about thymus
- 11:51Speaker 2: function restoration treatments. While stem cell therapies show promise in
- 11:55Speaker 2: regenerating the thymus, traditional management methods like hormone replacement therapy
- 12:00Speaker 2: still play a critical role. Some argue that gene therapy
- 12:03Speaker 2: could be the future, but we are still learning about
- 12:06Speaker 2: the long-term efficacy and safety of these treatments.
- 12:09Speaker 1: Which opens up a whole new set of ethical considerations.
- 12:13Speaker 1: How do we balance the potential of gene therapy with
- 12:15Speaker 1: the risks and uncertainties? And on a practical level, how
- 12:20Speaker 1: do we ensure that these treatments are accessible and affordable
- 12:23Speaker 1: for all patients, not just those with means?
- 12:26Speaker 2: You hit the nail on the head. The ethics of
- 12:28Speaker 2: genetic testing and gene therapy are a contentious area. They
- 12:32Speaker 2: involve complex issues of consent, privacy, and the potential for
- 12:36Speaker 2: widening healthcare disparities. It's crucial to have open discussions involving
- 12:41Speaker 2: not just medical professionals, but also ethicists and patients themselves
- 12:46Speaker 2: to ensure that the advancements in gene therapy are used responsibly.
- 12:51Speaker 1: And finally, let's not forget the patient experience. Living with
- 12:55Speaker 1: DiGeorge syndrome can be tough both physically and emotionally. How
- 12:59Speaker 1: can we support patients and their families beyond just medical interventions?
- 13:03Speaker 1: What kind of holistic care can we provide to improve
- 13:06Speaker 1: their quality of life?
- 13:07Speaker 2: Holistic care is indeed key. It's about addressing not just
- 13:10Speaker 2: the physical symptoms, but also the mental and social aspects.
- 13:14Speaker 2: Support organizations play a vital role, but we also need
- 13:18Speaker 2: better integration of mental health services and ongoing psychosocial support
- 13:22Speaker 2: for patients and their families. This comprehensive approach can significantly
- 13:26Speaker 2: enhance their overall well-being.
- 13:28Speaker 1: Well, Thomas, you have provided some fascinating insights. It's clear
- 13:33Speaker 1: that there are still many layers to uncover in the
- 13:35Speaker 1: journey of die-George syndrome. But with ongoing research and discussions
- 13:40Speaker 1: like these, We are moving forward in making life better
- 13:43Speaker 1: for those living with the syndrome. So, Thomas, moving forward,
- 13:47Speaker 1: let's dive into some emerging technologies. You mentioned gene therapy.
- 13:53Speaker 1: Can you tell us more about how it's being explored
- 13:56Speaker 1: for treating DiGeorge syndrome?
- 13:58Speaker 2: Absolutely, Rachel. Gene therapy is a game changer here. Essentially,
- 14:04Speaker 2: it involves editing the DNA where the TBX1 gene is
- 14:07Speaker 2: missing or defective. which could potentially restore the function of
- 14:11Speaker 2: the thymus, a key organ for T-cell development. The idea
- 14:16Speaker 2: is to introduce a functional copy of the TBX1 gene
- 14:20Speaker 2: into the affected cells, which could lead to normal thymus
- 14:23Speaker 2: function and a fully operational immune system.
- 14:26Speaker 1: That sounds revolutionary, but I bet there are still a
- 14:29Speaker 1: lot of questions and challenges to overcome. What are some
- 14:33Speaker 1: of the unresolved issues in this space?
- 14:35Speaker 2: Yes, there are definitely a few. One of the big
- 14:38Speaker 2: ones is identifying the optimal delivery method. Viral vectors are
- 14:43Speaker 2: a popular choice, but they can pose risks like inflammation
- 14:47Speaker 2: or even tumor formation. Researchers are also trying to address
- 14:51Speaker 2: the specificity of delivery. We need to ensure that the
- 14:55Speaker 2: gene is only delivered to the cells that need it
- 14:57Speaker 2: without causing any off-target effects.
- 14:59Speaker 1: And what about the future outlook? Where do you see
- 15:02Speaker 1: this going?
- 15:03Speaker 2: Well, it's exciting. Right now, Clinical trials are ongoing to
- 15:08Speaker 2: test the safety and efficacy of gene therapies for D.
- 15:11Speaker 2: George syndrome. If successful, these trials could pave the way
- 15:15Speaker 2: for personalized treatment options tailored to the individual's specific genetic makeup.
- 15:21Speaker 2: Imagine a future where a child born with this syndrome
- 15:24Speaker 2: could receive a one-time treatment that fundamentally restores their immune
- 15:28Speaker 2: function and reduces the need for lifelong medical interventions.
- 15:33Speaker 1: That's a lot of promise. but we shouldn't forget about
- 15:36Speaker 1: other emerging technologies like personalized treatment options. How do you
- 15:41Speaker 1: think these could change the game?
- 15:43Speaker 2: Exactly. Personalized treatments are key. The field is moving towards
- 15:48Speaker 2: using CRISPR and other genome. Editing tools to target and
- 15:52Speaker 2: correct specific genetic mutations in an individual context, this could
- 15:57Speaker 2: lead to more precise and effective treatments. For instance, if
- 16:00Speaker 2: a patient has a particular type of TBX1 deletion, The
- 16:04Speaker 2: treatment could be designed to address that exact mutation, providing
- 16:08Speaker 2: a more customized solution.
- 16:10Speaker 1: And what about the social and ethical considerations that come
- 16:14Speaker 1: with such advanced technologies? What does that all mean for
- 16:18Speaker 1: the patients and their families?
- 16:20Speaker 2: That's a good point, Rachel. As these technologies become more advanced,
- 16:24Speaker 2: we will need to consider how to support patients and
- 16:27Speaker 2: address their psychological and social needs. For example … They
- 16:31Speaker 2: might need psychological support to deal with the potential for
- 16:33Speaker 2: disappointment or to manage the expectations around such treatments. Ethical
- 16:38Speaker 2: considerations are also paramount, ensuring that we are not misusing
- 16:42Speaker 2: or over-promoting these technologies.
- 16:45Speaker 1: Right. And that's the tricky part. How can we ensure
- 16:48Speaker 1: that these advances are accessible and equitable for all? Not
- 16:52Speaker 1: just those who can afford the latest treatments.
- 16:55Speaker 2: Agreed. This will require a combination of public funding, regulatory oversight,
- 17:00Speaker 2: and equitable distribution strategies. We need policies that support research
- 17:05Speaker 2: and development while also ensuring that the benefits are shared widely. Plus,
- 17:10Speaker 2: to raise the challenge of building public trust and understanding
- 17:13Speaker 2: about these technologies so they are seen as beneficial and reliable.
- 17:17Speaker 1: Well, it's clear that the future looks very promising, but
- 17:21Speaker 1: to raise a lot of work ahead. Thomas, thank you
- 17:24Speaker 1: for shedding light on these areas.
- 17:26Speaker 2: Anytime, Rachel. Let's keep pushing forward and ensuring that everyone
- 17:31Speaker 2: has a fighting chance.
- 17:32Speaker 1: So, Thomas, what are the broader strategic implications of the
- 17:36Speaker 1: ongoing advancements in managing Digorge syndrome? How do these new
- 17:40Speaker 1: developments impact the approach to diagnosis and treatment?
- 17:44Speaker 2: Great question, Rachel. The strategic implications are multifaceted. First, the
- 17:50Speaker 2: integration of advanced genetic testing could significantly improve early detection.
- 17:55Speaker 2: This not only allows for more timely intervention, but also
- 17:58Speaker 2: reduces the psychological burden on families as they are better
- 18:02Speaker 2: prepared for the challenges ahead.
- 18:03Speaker 1: Exactly. Which brings up an interesting contradiction. While early detection
- 18:09Speaker 1: is crucial, the unpredictability of symptom manifestation can still complicate
- 18:15Speaker 1: the clinical approach. How do we balance these competing needs?
- 18:19Speaker 2: Well, it's like navigating a tricky maze. On one hand,
- 18:24Speaker 2: we have to be proactive with early detection and screening programs.
- 18:28Speaker 2: On the other, we need to be flexible and adaptable,
- 18:32Speaker 2: given the variability in symptoms. This requires a robust, multidisciplinary
- 18:37Speaker 2: care model that can respond to individual needs.
- 18:40Speaker 1: Right. And this leads us to another important point. How
- 18:44Speaker 1: do advancements in gene therapy and stem cell therapies fit
- 18:47Speaker 1: into this picture? Do they challenge or complement current clinical practices?
- 18:53Speaker 2: They certainly complement and potentially transform current practices. Gene therapy
- 18:58Speaker 2: offers the possibility of repairing the root, cause essentially addressing
- 19:02Speaker 2: the genetic defect. Stem cell therapies, meanwhile, may provide a
- 19:07Speaker 2: means to replace or repair damaged tissues. Both of these
- 19:11Speaker 2: approaches could significantly alter future treatment paradigms.
- 19:15Speaker 1: That's wild when you look at the raw numbers. In
- 19:18Speaker 1: the past, The limitations of current treatments meant managing symptoms
- 19:22Speaker 1: with a cocktail of medications and surgeries. But with these
- 19:26Speaker 1: new avenues, the potential for root-level solutions looks promising.
- 19:31Speaker 2: Absolutely. And it's not just about the technical feasibility. Ethical considerations,
- 19:37Speaker 2: patient consent, and equitable access will be crucial. We need
- 19:41Speaker 2: to ensure these breakthroughs benefit the broadest possible patient population,
- 19:45Speaker 2: not just those who can afford expensive treatments. True.
- 19:49Speaker 1: The future is real. bright, but the journey to get
- 19:51Speaker 1: there isn't smooth. It involves addressing the very real concerns
- 19:56Speaker 1: about genetic privacy, informed consent, and the potential for societal
- 20:00Speaker 1: bias in access to these new treatments.
- 20:03Speaker 2: Exactly. And let's not forget, to raise a whole ecosystem
- 20:06Speaker 2: of stakeholders— pharmaceutical companies, policy makers, patient support organizations, each
- 20:12Speaker 2: has a role to play and coordinating their efforts will
- 20:15Speaker 2: be essential for success.
- 20:17Speaker 1: Definitely. It's a complex web, but one that we can navigate.
- 20:21Speaker 1: The key is a collaborative, holistic approach that considers both
- 20:25Speaker 1: the technical innovations and the human aspects of patient care.
- 20:29Speaker 2: Precisely. We are at a critical juncture where all these
- 20:33Speaker 2: elements come together. The next few years will determine how
- 20:37Speaker 2: effectively we can leverage these advancements to improve the quality
- 20:40Speaker 2: of life for those with D. George syndrome.
- 20:43Speaker 1: That brings us to the end of today's episode. Thank
- 20:45Speaker 1: you so much for spending part of your day with me.
- 20:48Speaker 1: If you found this episode's tips helpful and want to
- 20:51Speaker 1: make sure you don't miss the next conversation, please take
- 20:54Speaker 1: a quick second to hit that subscribe or follow button
- 20:56Speaker 1: on whatever platform you are listening on. It's a completely
- 21:00Speaker 1: free way to support the show and helps more people
- 21:02Speaker 1: find us. This podcast is independently produced, so if you
- 21:06Speaker 1: are ever in a position where you would like to
- 21:08Speaker 1: help keep it running, we do accept small donations. You
- 21:12Speaker 1: can find a link right in the episode description below
- 21:15Speaker 1: to buy us a coffee or contribute what you can.
- 21:18Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 21:23Speaker 1: and we will talk again soon.